You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

10 Results
Drug
Other Name(s): Alkeran®
Jun 2019
Drug
Other Name(s): Purinethol®
Jun 2019
Drug
Other Name(s): Lysodren®
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    melphalan - oral tablets
ODB - General Benefit
    prednisone
Jun 2019
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
  • melphalan - oral tablets
ODB - General Benefit
  • prednisone
Exceptional Access Program
  • thalidomide - Multiple myeloma in patients ≥65 years of age in combination with melphalan and prednisone, with specific criteria
Jun 2019
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer
Jan 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
Jan 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Palliative
Feb 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Mar 2025